Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

Japanese approvals include Tecentriq for TNBC
Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin modulator and stimulator Trintellix vortioxetine from H. Lundbeck A/S

Read the full 437 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE